Deficiency of huntingtin interacting protein 1 (Hip1) results in degenerative phenotypes. 48
HIP1 was originally discovered as a protein that interacts with Huntingtin, the 67 protein product of the gene mutated in Huntington's disease (1, 2). HIP1 was later found 68 to be an endocytic protein that binds clathrin, AP2 (3-6), inositol lipids (7-9) and actin 69 (10). Knockout of Hip1 alone (11, 12) or with its only known mammalian relative, Hip1-70 related (Hip1r) (13, 14) , results in a degenerative phenotype. This phenotype, which is 71 more severe in double-knockout mice, includes testicular degeneration, spinal defects, 72 and lowered body weight. Although it has been shown that endocytosis of AMPA 73 receptors in neurons is disrupted in knockout mice (11), mechanisms for most of the 74 knockout phenotypes are unknown as are the roles of HIP1 in normal and neoplastic 75 tissues. 76 HIP1 was first linked to receptor tyrosine kinase (RTK) signaling when it was 77 identified as a chromosomal translocation partner with the platelet-derived growth factor 78 β receptor (PDGFβR) gene in leukemia (15). This HIP1/PDGFβR translocation is a 79 member of a large family of chromosomal translocations involving the PDGFβR gene 80 (16) (17) (18) (19) . Recently, others have identified HIP1 as a partner in chromosomal 81 translocations involving the anaplastic lymphoma kinase (ALK) gene in non-small cell 82 lung cancer (20) (21) (22) . Like HIP1/PDGFβR, the HIP1/ALK translocation is a member of a 83 large family of chromosomal translocations that involve the ALK gene. 84
In addition to the HIP1/PDGFβR and HIP1/ALK mutations, the HIP1 protein 85 itself is expressed at high levels in several other cancers (23-25) and overexpression of 86 HIP1 transforms fibroblasts (24) and prostate epithelial cells (26). This transforming 87 activity is also linked to RTKs, as HIP1-transformed cells display increased levels of 88 EGF receptor (EGFR) (24). Indeed, HIP1 prolongs the half-lives of RTKs, such as EGFR 89
and PDGFβR (8). Additionally, treatment of the HIP1-transformed cells with an EGFR 90 inhibitor reverses the transformed phenotype (24). One possible explanation for EGFR 91 overexpression in these cancers is that HIP1-dependent stabilization of RTKs occurs via 92 clathrin or membrane vesicle sequestration. Low levels of clathrin or altered membrane 93 dynamics could decrease endocytosis-mediated RTK degradation. This would then 94 prolong RTK signaling and promote transformation. 95
Here, we generated Hip1 deficient mice with the option to conditionally express a 96 single copy of human HIP1 in specific tissues to investigate how Hip1 deficiency leads to 97 degeneration. With this new model, we discovered that the brain does not require Hip1 98
for normal physiology, but that Hip1 expression in spleen, liver, and kidney may be 99 important for normal physiology. We also assayed a variety of Hip1 deficient tissues for 100 alterations in metabolism and gene expression and discovered that low phosphocholine 101 (PC) levels and Gdpd3 expression were associated with Hip1 deficiency. We also 102 observed Gdpd3/Hip1 double deficient mice to have spinal degeneration at younger ages 103 compared to single Hip1 deficient mice suggesting Gdpd3 partially compensates for the 104 Hip1 deficiency. Low PC levels in Hip1 deficient tissue is opposite to elevated levels of 105 HIP1 and PC found in cancers (27).Thus, HIP1 may, via endocytosis of lipids or via 106 effects on gene expression, lead to normal or abnormal levels of choline-related 107 metabolites in both healthy and diseased tissues. 
MATERIALS AND METHODS 112

Generation of Hip1 deficient mice and conditional HIP1 knockin mice 113
The targeting vector was constructed to generate a knock-in mouse allele that 114 conditionally expresses human HIP1 and enhanced GFP (EGFP; Figure 1A) . The 115 objective of this project has been to create a knock-in mouse model conditionally 116 expressing human Hip1 and eGFP using homologous recombination in mouse C57BL/6 117 embryonic stem cells and subsequent blastocyst injection of the appropriate targeted ES 118 cells to create the gene targeted mice. 119
The mouse Hip1 genomic DNA sequence was retrieved from mouse chromosome 120 5 from the Ensembl database and used as reference in this project. The mouse BAC DNA 121
containing Hip1 gene was used as templates for generating the homology arms and the 122 southern probes for screening targeted events. The 5' homology arm (~5.4 kb, LHA) and 123 the 3' homology arm (~3.6 kb, SHA) were generated by PCR using high fidelity Taq DNA 124 polymerase. The Lox-Stop-Lox cassette (~1.5 kb, LSL) was amplified from LSL-pZero-2 125 vector. These fragments were cloned in the FtNwCD or pCR4.0 vector, and were 126 confirmed by restriction digestion and sequencing. The hHip1 cDNA (~3 kb) was 127 cells). Unique restriction sites SacII and PacI were added to flank the hHip1 cDNA for 135 easy swapping in mutant cDNA in the future. Generation of Gdpd3 deficient mice The targeting strategy for the generation of 156 the Gdpd3 knockout allele was based on NCBI transcript NC_000073_NM_024228_2 157 ( Figure 5A) . The constitutive Gdpd3 knock out mouse was generated with the assistance 158 of Taconic biosciences and CRISPR/Cas9-mediated genome editing. Of all potential 159 sgRNAs, two were selected for their position and minimal potential off-target effects. 160
Guide RNAs target sequences before exon 2 (proximal sgRNA, 5'-GAG AGG CCA GTT 161 CAA CTG AT-3') and after exon 6 (distal sgRNA, 5'GAC GGG GAT TCG ACA ATT 162 GC-3'). The resulting alteration via Non-Homologous End Joining (NHEJ) deleted the 163 functionally critical exons (2-7), generated a frame-shift mutation from exon1 to all 164 downstream exons and introduced a premature Stop codon in exon 7. In addition, the 165 resulting transcript was predicted to be a target for non-sense mediated RNA decay and 166 therefore not expressed at a significant level. The guide RNAs and Cas9 mRNA/protein 167 were injected into single celled zygotes. C57BL/6J mice were used to generate these mice. 168
Mice were tail genotyped using the following primers: 169
Oligo-1 5'-TCC ATG TAG GGT GGA GTG AGC-3' 170
Oligo-2 5'-AAG GGG CTC GTA GGG GAA G-3' 171
Oligo-3 5'-ACA CAG GAA GGA CCA GGG C-3' 172
Amplicon sizes for the wild type allele was 501 bp (with oligos 1 and 3) and for the 173 deletion allele was 295 bp (with oligos 1 and 2). These PCR products were cloned and 174 sequenced. Indel modifications were distinguished from unmodified wildtype sequences 175 by heteroduplex analysis via capillary electrophoresis. (1:1,000) or anti-mouse Hip1 1B11 (1:1,000) and rabbit polyclonal anti-human HIP1 198 UM410 and UM323 (1:5,000). Blots were then incubated with horseradish peroxidase 199 (HRP)-conjugated mouse or rabbit secondary antibodies (1:10,000; GE healthcare) and 200 developed using chemiluminescence (Pierce). 201
Metabolomics Mouse tissues from age matched Hip1 deficient (n=7) and HIP1 202 rescued (n=7) or Gdpd3 +/+ (n=5) and Gdpd3 -/-(n=5) mice were rapidly removed (within 2 203 minutes of sacrifice) and snap frozen. Hip1 deficient mice were <3 months of age. Gdpd3 204 knockout mice were 2-6 months of age. Frozen tissues (~100mg each) were homogenized 205 in ice-cold 80% methanol. Following a vigorous vortex, cell debris was removed by 206 centrifugation. The supernatant was evaporated with a SpeedVac to generate a metabolite 207 pellet which was reconstituted in 0.03% formic acid in analytical-grade water before 208 liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. LC-MS/MS 209 was performed as described previously (31). 210
To gain an initial overview of the results, a multivariate principle component 211 analysis of all 120 metabolites that were measured was performed. All analyses were 212 carried out using SIMCA-P (version 13.0.1; Umetrics). Although there were some 213 differences between the two genotypes, the main changes were in choline metabolites as 214 T7 oligo(dT) primer to generate single stranded cDNA followed by a second strand 226 synthesis to generate double stranded cDNA which was then column purified. In vitro 227 transcription with T7 RNA polymerase generated biotin-labeled cRNA. The cRNA was 228 then column purified, checked for size and yield using the Bio-Rad Experion system, and 229 1.5ug of cRNA was hybridized to each array using standard Illumina protocols. 
Generation of a knock-in allele of human HIP1 246
Here, we report the generation of a novel Hip1 knockout allele (Hip1 LSL ; Figure  247 1A). This allele also has the human HIP1 cDNA knocked into the mouse Hip1 locus 248 downstream of a loxP-flanked transcriptional stop cassette (LSL). Having previously 249
found that a multi-copy-transgenic HIP1 cDNA allele was able to rescue the Hip1 and 250
Hip1r double knockout degenerative phenotype (13), we hypothesized that HIP1 as a 251 single copy allele may also substitute for Hip1 (or Hip1r) deficiency phenotypes. This 252 conditional knock-in allele allows for use of specific Cre alleles to guide tissue-specific 253 HIP1 expression together with the endogenous mouse Hip1 promoter to further regulate 254 expression. In addition to the conditional nature of this allele that allows for expression of 255 HIP1 in specific tissues at specific times, there were other potential advantages of this 256 targeting strategy. First, since HIP1 is expressed at high levels in many cancers (24, 25, 35, 257 36), humanization of a mouse allele could be of future use for preclinical in vivo HIP1 258 targeted drug testing. Second, this type of humanization addresses the question of whether 259 the many introns of the large 250 Kb Hip1 locus are required for regulation of the Hip1 260
gene. We reasoned that if the expression of HIP1 from a single knocked-in copy does not 261 restore normalcy to the Hip1 deficient mice, the complex genomic structure of the allele is 262 necessary for HIP1 expression. 263
We successfully targeted ES cells ( Figure 1B) and generated three independent 264 mouse lines carrying the Hip1 LSL allele (the "knockout" allele). Homozygous and 265 heterozygous knockout mice were born at predicted Mendelian frequencies. To generate 266 the germline "humanized" allele, Hip1 LSL/+ mice were crossed with transgenic CMV-Cre 267 mice (28). The CMV promoter is activated in all tissues including germ cells. The resulting 268 Hip1 HIP1 humanized allele was used to generate fully humanized, Hip1 HIP1/HIP1 mice 269 (CMV-Cre allele was crossed out). Hip1 HIP1/HIP1 mice could be distinguished from Hip1 270 knockout (Hip1 LSL/LSL ) mice by GFP expression in peripheral blood (Figure 1C) or by the 271 presence of human HIP1, rather than mouse Hip1 protein, in mouse tissues (Figure 1D,  272   bottom) . (Figure 1D, top) and were without a 278 kypholordotic spine (Figures 1E) . These data indicate that a single copy of human HIP1 279 cDNA is able to fully substitute for the mouse Hip1 gene. This was also supported by the 280 ability of the Hip1 HIP1 allele to fully rescue the Hip1/Hip1r double knockout phenotype, 281
which was more severe than in the single knockout mice (Figures 1F) . 282
HIP1 expression in the brain does not prevent the Hip1 knockout phenotype 283
Because Hip1 is expressed at high levels in the brain and the Hip1 protein interacts 284 with Huntingtin, the product of the gene mutated in Huntington's syndrome (1, 2), we next 285 asked if restricted expression of HIP1 in neural tissues would rescue the Hip1 deficiency 286 phenotypes. Because Hip1 has also been shown to be required for AMPA receptor 287 trafficking in neurons (11), we predicted HIP1 expression in the brain would rescue the 288 Hip1 deficiency phenotypes. To restrict HIP1 expression to neural tissue, we crossed the 289 Hip1 LSL /LSL mice with transgenic GFAP-Cre mice (30). The GFAP promoter in these mice 290 is active in most glial and neuronal cells of the brain and spinal cord. As expected, western 291 blot analysis of human HIP1 expression in GFAP-Cre; Hip1 LSL /LSL brains demonstrated 292 levels similar to the germline humanized Hip1 HIP1/HIP1 mouse brains and HIP1 protein was 293 not detected in spleen, lung, kidney or liver (Figure 2A) . To our surprise, the degenerative 294 phenotypes associated with Hip1 deficiency were not rescued by GFAP-Cre mediated 295 expression of HIP1 (Figure 2B) . These GFAP-Cre data suggest Hip1 deficiency in the 296 brain does not contribute to the Hip1 deficiency phenotype. 297
Mx1-Cre mediated HIP1 expression rescues Hip1 deficient mice 298
Next we crossed Hip1 LSL /LSL mice to Mx1-Cre transgenic mice to express HIP1 in 299 adult liver, kidney, and the hematopoietic system (29). We did this because these tissues 300 express high Hip1 levels and the Hip1 deficiency phenotype develops only in adulthood. 301
The Mx1 promoter is activated by interferon, which can also be induced by the synthetic 302 double-stranded RNA, polyinosinic-polycytidylic acid (pIpC) (29). Mice were induced 303 with pIpC at 6 weeks of age prior to the onset of the degenerative phenotype. The induced 304 Mx1-Cre;Hip1 LSL/LSL mice (n=5) were of normal weight (Figure 2C) and without spinal 305 defects at 4 months of age (Figure 2D) , whereas induced Hip1 LSL /LSL littermates were 306 severely affected with the degenerative phenotype. 307
The pIpC induced Hip1 LSL/LSL mice and Mx1-Cre;Hip1 LSL/LSL rescued mice were 308 evaluated for human HIP1 expression to confirm specificity of the Cre allele. Western blot 309
analyses for human HIP1 protein demonstrated that pIpC-induced recombination occurred 310 most effectively in spleen and liver. Kidney did not show as robust HIP1 expression. As 311 expected, HIP1 was not detected in brain or lung tissues (Figure 2E) . These Mx1-Cre data 312 suggest that Hip1 deficiency in adult liver and/or hematopoietic tissues (and less likely 313 kidney) contributes to development of Hip1 deficiency phenotypes. 314
Bone marrow transplant of wild type bone marrow does not prevent the Hip1 315 knockout phenotype 316
We transplanted wildtype bone marrow into Hip1 deficient mice to test if 317 replacement of the Hip1 deficient bone marrow with normal bone marrow could rescue 318 the kypholordotic phenotype. Bone marrow cells from 6-week-old wildtype (CD45.1 + ) or 319
Hip1 LSL/ LSL mice were transplanted into 6-week-old lethally irradiated Hip1 LSL/ LSL mice 320 (CD45.2 + ) (n=5 per group). These mice all developed a kypholordotic phenotype 321 indicating that irradiation, wild type bone marrow (confirmed by the replacement of the 322 CD45.2 + cells by CD45.1 + cells), or the transplant process in general does not prevent the 323 phenotype (Figure 2F) . 324
We also transplanted Hip1 deficient bone marrow into wild type mice to test if 325
Hip1 deficiency in bone marrow can cause the development of the Hip1 mutant 326 kypholordotic phenotype. Whole bone marrow cells from 6-week-old Hip1 LSL / LSL 327 (CD45.2 + ) mice were transplanted into 6-week-old lethally irradiated wildtype (CD45.1 + ) 328 mice (n=18). These mice did not develop the phenotype despite living to one year of age. 329
Replacement of wildtype bone marrow with Hip1 deficient bone marrow was confirmed 330
by replacement of CD45.1 + cells by CD45.2 + cells (data not shown). In sum, Hip1 331 deficiency in bone marrow is insufficient for the development of the phenotype and Hip1 332 expression in the bone marrow is insufficient for the rescue of the phenotype. 333
Hip1 deficient tissues have low phosphocholine (PC) levels 334
The adult onset weight loss, generalized weakness and spinal defects of Hip1 335 deficient mice raise the possibility of a progressive metabolic defect. Prior investigations 336 to identify abnormalities in specific Hip1 deficient cell types, such as osteoblasts or 337 osteoclasts, or to identify endocrine abnormalities (e.g. altered thyroid or other hormone 338 levels) were tested and eliminated (13). We therefore used mass spectrometry to compare 339 levels of >100 metabolites in wildtype versus Hip1 deficient tissues. Deletion of Hip1 340 resulted in altered concentrations of multiple choline related metabolites, although choline 341 levels were not changed in any tissues tested (brain, kidney, lung, liver, spleen). The most 342 striking change was in phosphocholine (PC) which is generated by phosphorylation of 343 choline by choline kinase. PC was significantly decreased in all Hip1-deficient tissues 344 tested, except brain where it still trended low (Figure 3A, B) . The largest observed 345 decrease in PC was in the liver (by 0.41-fold, p=0.0003, VIP=1.8343), a tissue where 346 choline metabolism is particularly relevant (Corbin and Zeisal, 2012). Because PC is a 347 sentinel choline metabolite that reflects overall phosphatidylcholine pathway homeostasis 348 (37), these data suggest a general change in choline metabolism that results from loss of 349 homocysteine to cysteine which is then converted to cystathionine). However, vitamin B6 360 levels were normal in the serum of Hip1 deficient mice (data not shown). Increased 361 homocysteine could also be due to an altered methionine cycle. In fact, S-362 adenosylhomocysteine (SAH) levels were increased and S-adenosyl methionine (SAM) 363 levels were decreased in several tissues of Hip1 deficient mice (DATASET S2), suggesting 364 changes in steady state methylation. However, we did not detect changes in histone 365 methylation by western blot analysis in tissues or by mass spectrometry (data not shown). 366
Another possibility is that increased homocysteine was simply due to altered choline 367 metabolism. Choline is metabolized to betaine, which acts as a methyl donor in the 368 conversion of homocysteine to methionine. Since the liver showed the greatest decreases 369 in PC and acetylcholine and the greatest increase in homocysteine of all tissues tested, this 370 hypothesis is plausible. It is possible that high homocysteine redirects choline for betaine 371 synthesis at the expense of acetylcholine and PC in order to maintain methionine 372 homeostasis. In sum, these data suggest that Hip1 deficiency results in altered choline 373 metabolism that includes elevated homocysteine levels. 374
Hip1 deficient mice lose Gdpd3 expression 375
In order to identify potential mediators of the Hip1 deficiency phenotypes and the 376 altered metabolome, we compared gene expression profiles from tissue of Hip1 +/+ , 377
Hip1 LSL/LSL , and Hip1 HIP1/HIP1 mice by microarray analysis. As expected, mouse Hip1 was 378 not expressed in either Hip1 LSL/LSL knockout or Hip1 HIP1/HIP1 rescued mice but was 379 expressed in Hip1 +/+ wildtype mice (data not shown). We identified Gdpd3 (also known 380 as Gde7) as a gene with a robust and reproducible decrease in expression in all tested tissues 381 (DATASET S4). Gdpd3 is a gene whose protein product is a member of a 382 glycerophosphodiester phosphodiesterase domain (Gdpd) family of enzymes, also known 383 as the Gde family (38, 39) . Expression patterns of the six other known members of the 384 Gdpd family were not changed in Hip1 deficient mice (Figure 4A) . These decreases of 385
Gdpd3 expression were confirmed with qPCR ( Figure 4B) . Decreased expression of 386
Gdpd3 is not a consequence of the kypholordic phenotype since young, phenotypically 387 "normal" Hip1 deficient mice show reduced Gdpd3 expression levels similarly to old, 388 kypholordotic mice (data not shown). 389
Generation and analysis of Gdpd3 knockout allele 390
To understand the physiological importance of Gdpd3 and to test whether Gdpd3 391 contributes to the Hip1 deficiency phenotypes, we generated a Gdpd3 knockout allele by 392 CRISPR-mediated deletion of exons 2-7 (Figure 5A, B) . Homozygous and heterozygous 393 knockout mice were born at predicted Mendelian frequencies and were indistinguishable 394 at birth from wild type littermates. Levels of Gdpd3 mRNA in lung and spleen reflected 395 the heterozygous and homozygous state of the knockout mutation (Figure 5C) . 396
Heterozygous knockout tissues expressed approximately half the amount of Gdpd3 397 message compared to wildtype tissue, and homozygous knockout tissue had no detectable 398
Gdpd3 message. In contrast, Gdpd3 deficiency did not alter Hip1 mRNA levels 399
indicating that Hip1 expression is not regulated by Gdpd3. 400
Both male and female Gdpd3 deficient mice were fertile with normal litter sizes 401 and gender distributions. Unlike Hip1 knockout mice who were afflicted with male 402 infertility, as well as weight loss and a kypholordotic spinal defect by six months of age, 403
Gdpd3 knockout mice displayed no consistent defects even at 2 years of age (data not 404 shown). Analysis of hematoxylin and eosin stained tissues showed no abnormalities in 405
Gdpd3 knockout mice compared to age and gender matched controls. 406
Gdpd3 knockout mice show no changes in phosphocholine (PC) 407
Gdpd3 has lysophosphatidylcholine (LPC)-specific PLD (LysoPLD) activity that 408 can generate lysophosphatidic acid (LPA) and choline (37, 38). In the first step in the 409 biosynthesis of phosphatidylcholine, choline is phosphorylated to generate PC. We 410 hypothesized, that the decrease in Gdpd3 in Hip1 deficient mice could lead to the observed 411 low PC levels (Figure 6) . As with Hip1 deficient tissues, we used mass spectrophotometry 412 to profile metabolites in wild type and Gdpd3 deficient tissues. Samples were prepared 413 from age-and gender-matched Gdpd3 +/+ and Gdpd3 -/mice. To our surprise, choline and 414 related metabolites (including PC) were at normal levels in Gdpd3 deficient mice 415 (DATASET S5). Unlike with Hip1 deficient tissues, deletion of Gdpd3 resulted in fewer 416 perturbations in the metabolic profile where only a small number of metabolites showed 417 modest changes in concentration (DATASET S6). It is possible that in the absence of 418
Gdpd3, other Gdpd family members (e.g. Gdpd1 that is also thought to be a lysoPLD 419 enzyme) compensate for its functions. 420
Hip1/Gdpd3 double knockout (DKO) mice 421
Gdpd3 deficiency hastened the onset and severity of the degenerative phenotype 422 caused by Hip1 deficiency. The time of onset of the kypholordosis as detected by 423 palpation in Hip1/Gdpd3 DKO mice was significantly earlier compared to Hip1 single 424 knockout mice (Figure 5D ). All phenotyping was performed by an investigator (G.L.P.) 425 blinded to genotype. There was no difference in the time of onset of phenotype between 426 Hip1 LSL/LSL and Hip1 LSL/LSL ; Gdpd3 +/mice (data not shown). In a majority of cases, by 427 the time of sacrifice due to failure to thrive, the angle of the thoracic curvature was 428 smaller (more severe) in DKOs compared to age-and gender-matched single Hip1 429 knockout mice (Figure 5E) . These data indicate that Gdpd3 and Hip1 compensate for 430 one another to maintain spinal homeostasis. These data also suggest that the diminished 431
Gdpd3 expression in the Hip1 knockout mouse tissues (Figure 4) contributes to the Hip1 432 knockout phenotype and the remaining small amounts of Gdpd3 provide some protection. 433
434
DISCUSSION 435
The role of HIP1 in leukemia (15) and lung cancer (20-22) as an oncogenic fusion 436 partner and the necessity of Hip1 for mouse homeostasis are well established (11, 12) . 437
Additionally, HIP1 itself is upregulated in many cancers (24, 25, 35, 36) and prognostic in 438 prostate cancer (25). However, mechanisms for how HIP1 overexpression contributes to 439 transformation (24, 26) and how its deficiency in mice leads to degeneration are not known. 440
Because HIP1 binds to clathrin and AP2 (3-6) and alters endocytosis in cultured cells when 441 perturbed (40), disrupted endocytosis that results from HIP1 abnormalities is a reasonable 442 hypothesis for possible mechanisms to cancer, as well as mechanisms to degeneration (41). 443
HIP1 is a large 250 kb, 32 exon gene and its second intron is a rare regulatory 444 ATAC intron (42); its complex gene structure suggests that the introns and potential 445 alternative splice products are important for maintenance of its "normal" levels. However, 446
here we generated a Hip1 targeted constitutive knockout with the option of conditional re-447 expression from a humanized allele. We showed that a single copy human HIP1 cDNA 448 (intron-free with the exception of intron 1), when present in all cells of the mouse 449 (germline), was able to fully rescue Hip1 deficiency phenotypes. Therefore, alternative 450 splicing and most of the intervening sequences are not necessary for normal HIP1 levels 451 and functions. 452
Our novel conditional Hip1 allele allowed us to use multiple Cre alleles to express 453 Hip1 in a tissue-specific manner to understand the role of Hip1 in spinal homeostasis. To 454 our surprise re-expression of HIP1 specifically in the adult hematopoietic system, kidney 455 and liver by induction of Mx1-Cre with pIpC was sufficient to prevent development of the 456 Hip1 deficiency phenotypes. Using bone marrow transplantation of Hip1 knockout bone 457 marrow into lethally irradiated wild type mice, we found Hip1 deficiency in the bone 458 marrow did not result in development of the Hip1 deficiency phenotype. In contrast, robust, 459 but restricted, expression of HIP1 in the central nervous system (both neurons and glia) 460 using a GFAP-Cre transgene was insufficient to prevent the Hip1 deficiency phenotypes. 461
These data indicate that expression of a HIP1 cDNA in spleen, kidney and/or liver, but not 462 in the brain, is required for mouse homeostasis. 463
To explore mechanisms for how Hip1 is required for homeostasis we analyzed the 464 metabolomes and transcriptomes of Hip1 deficient tissues. Hip1 deficiency was associated 465 with reduced PC levels and reduced Gdpd3 expression levels. Specifically, Hip1 deficiency 466 was associated with low liver, kidney and spleen PC levels. PC levels in the brain were 467
normal. This correlates with the rescue of the Hip1 deficiency degenerative phenotypes 468 with HIP1 expression in adult liver, kidney and spleen, but not with HIP1 expression in the 469 brain. The lack of PC depletion in the brain implies either that Hip1 is not involved in 470 maintaining brain PC levels or that redundant metabolic mechanisms exist to ensure 471 choline homeostasis in the brain. In fact, the capacity of neurons to synthesize choline de 472 novo is limited and most neuronal choline comes from influx through a high-affinity 473 choline transporter CHT1 (43). Lack of Hip1 may therefore be less likely to lead to 474 decreased steady state PC levels in the brain compared to other tissues. 475
Gdpd3 (Gde7) is a member of the mammalian glycerophosphodiester 476 phosphodiesterase domain containing (Gdpd) gene family (Figure 4A) (38, 39) . The 477 common GDPD domain suggests potential functions for this family in phospholipid 478 metabolism. However, the substrate specificity and specific enzymatic activity, as well as 479 the physiological functions of proteins encoded by this gene family are not well 480 understood. As recombinant proteins, both Gdpd3 (Gde7) and Gdpd1 (Gde4; Gdpd3's 481 closest relative) have been shown to have lysoPLD activity that catalyzes the formation of 482 LPA and choline (44, 45) . LysoPLD activity of Gdpd3 makes it plausible that low Gdpd3 483 expression in Hip1 deficient mice led to perturbations in choline-related metabolites as 484 discussed in the results section. 485
The lysoPLD activity of Gdpd3 predicts that LPA may be decreased in Hip1 486 deficient mice. We did, in fact, measure LPA levels in serum and tissue but found no 487 changes with the exception of a slight elevation in Hip1 deficient liver tissue (data not 488 shown). However, serum LPA (considered tumorigenic (46)) is generated by Autotaxin, a 489 PLD located on the outside surface of the cell (47). Because GDPD3 is intracellular (39), 490
it less likely to contribute to serum LPA levels and it is not surprising that we do not see 491 changes in serum LPA in Hip1 deficient mice (Figure 6) . The high abundance of 492 extracellular/serum LPA can complicate the measuring of tissue/intracellular LPA. Any 493 changes in intracellular LPA levels that may occur due to loss of Gdpd3 may be 494 confounded by serum/extracellular LPA. 495
Because HIP1 is expressed at high levels in many cancers (25) and can directly 496 transform cells (24), this newly discovered alterations in choline-related metabolite levels 497 in the Hip1 deficient mice may not only help unravel the mechanism of degeneration 498 associated with Hip1 deficiency, but also help explain how HIP1 overexpression 499 transforms cells -especially since abnormal choline phospholipid metabolism (elevated PC 500 and diminished GPC) is an emerging hallmark of cancers (27, 48) . In fact, prior published 501 data converge on a connection between HIP1, GDPD3, cancer and choline. Specifically, 502
Gdpd3 has been found to be upregulated in mouse multiple myeloma (49, 50), HIP1 is 503 required for growth of multiple myeloma cells (51), and transgenic overexpression of HIP1 504 induces myeloma like neoplasms in mice (52). 505
In addition to Gdpd3, other GDPDs have been implicated in cancers and choline 506 pathways. For example, GDPD5 (GDE2) is elevated in breast cancer and has been 507 correlated with elevated PC levels (53). GDPD5 has GPC-phosphodiesterase activity that 508 generates PC. Dysregulation of choline metabolism may therefore be a shared mechanism 509 for how altered GDPD family members could contribute to cancer development. However, 510 each member of the GDPD family of enzymes is thought to have unique activities and 511 unique substrate specificities; our understanding of their activities and metabolic effects 512 will only be increased with additional, detailed in vivo studies. 513
Since HIP1 is a member of a group of endocytic oncoproteins that are hypothesized 514 to usurp normal endocytic pathways to transform cells by increasing tumor-promoting 515 signals (54), the decreased PC levels in the knockout mice add a new layer of complexity 516 to the endocytosis and cancer hypothesis. By altering membrane trafficking, aberrant 517 endocytic factors such as HIP1 could simultaneously elevate levels of several growth factor 518 receptors by altering their endocytosis (41, 54), and also by influencing membrane lipid 519 composition. It has already been shown that inhibition of endocytosis can lead to changes 520 in membrane lipid composition (55), and that changes in membrane lipid composition 521 effect endocytosis of membrane receptors (56). These changes in membrane lipid 522 composition and altered receptor signaling could then influence or be influenced by choline 523 pathway enzymes, such as Gdpd3, through feedback loops that increase PC levels in cancer 524 and decrease PC levels in degeneration. 525
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